Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Australia opens up more borders in domestic travel boost, eyes vaccine

11/23/2020 | 07:10pm EST

* Queensland to allow visitors from NSW, Victoria

* Internal border openings to spur domestic tourism

* AstraZeneca vaccine seen available in March - minister

* NSW premier confirms breaching COVID isolation rules

SYDNEY, Nov 24 (Reuters) - Australia will lift more internal state border restrictions in a boost for tourism as new coronavirus infections slow to a trickle, while the first vaccines could be available in March, a government minister said on Tuesday.

Queensland state, a popular holiday destination, will allow visitors next week from the country's two most populous states, New South Wales (NSW) and Victoria, after closing its borders in August.

NSW has since notched a month without any COVID-19 cases where the source is unknown and restrictions on arrivals from Sydney will be eased on Dec. 1, Queensland Premier Annastacia Palaszczuk said.

Residents of Victoria, previously the country's coronavirus hotspot, will also be welcomed if the state has no new cases on Wednesday, which would mark 26 days without community transmission.

"Queensland is good to go," Palaszczuk told reporters in Brisbane.

NSW and Victoria opened their border on Monday, while the South Australia-Victorian border opens fully next week, in welcome news for local airline companies, Qantas Airways and Virgin Australia.

Qantas said it would run more than 1,200 return flights from Victoria and NSW into Queensland in the run-up to Christmas.

The moves will please Prime Minister Scott Morrison, who has pushed state leaders to relax some curbs to help revive an economy that shrank 7% in the three months to end-June, the most since records began in 1959.


Looking further out, Health Minister Greg Hunt said Australia - which has agreed to buy nearly 34 million doses of AstraZeneca's COVID-19 vaccine - is increasingly confident it can complete a vaccination programme after the release of preliminary trial results.

"Our vaccine timeline is beginning to strengthen. The news from overseas is that we are on track for first vaccines in March," Hunt told reporters in Sydney.

AstraZeneca said its COVID-19 vaccine, cheaper to make, easier to distribute and faster to scale-up than its rivals, could be as much as 90% effective.

Australia has reported more than 27,800 cases of COVID-19 and 907 deaths since the pandemic began, but estimates there are fewer than 100 active COVID-19 cases remaining, mostly people in hotel quarantine.

Victoria said on Tuesday it had zero active cases for the first time in more than eight months following a strict lockdown after daily infections peaked at more than 700 in early August.

Qantas, meanwhile, said it would insist in future that international travellers have a COVID-19 vaccination before they fly, describing the move as "a necessity".

"We are looking at changing our terms and conditions to say, for international travellers, that we will ask people to have a vaccination before they can get on the aircraft," Chief Executive Alan Joyce told broadcaster Channel Nine.

That approach may not be a global model because it would bar some people from travelling, the head of airline body IATA said. Testing was "more critical to reopening borders than the vaccine", Alexandre de Juniac told Reuters.

Lufthansa and Ryanair also said they did not expect any vaccine requirement, with the low-cost carrier's CEO Michael O'Leary citing EU free movement rules.

Australia closed its international borders in March and currently requires returning travellers from overseas to quarantine for two weeks. (Reporting by Colin Packham and Renju Jose; Additional reporting by Laurence Frost in Paris; Editing by Richard Pullin, Michael Perry and Alex Richardson)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -2.18% 7779 Delayed Quote.8.57%
DEUTSCHE LUFTHANSA AG 4.17% 10.265 Delayed Quote.-8.89%
NUFARM LIMITED -2.11% 4.64 End-of-day quote.13.17%
QANTAS AIRWAYS LIMITED -1.65% 4.77 End-of-day quote.-1.65%
RYANAIR HOLDINGS PLC -4.40% 14 Real-time Quote.-9.90%
All news about ASTRAZENECA PLC
12:54pOxford scientists expect some vaccine data on UK mutant virus by next week
12:43pSHAREHOLDER ACTION ALERT : The Schall Law Firm Announces the Filing of a Class A..
12:22pASTRAZENECA : EU to Push AstraZeneca on Vaccine Delivery Agreement -- Update
12:03pBritish shares drop as lockdowns strain mining stocks; AstraZeneca weighs
11:52aASTRAZENECA : Oxford scientists expect some vaccine data on UK mutant virus by n..
11:39aAZN EQUITY ALERT : Labaton Sucharow Announces Filing of Securities Class Action ..
10:40aFrance's Sanofi to help rival Pfizer-BioNTech make vaccines
10:39aASTRAZENECA : Tensions rise as AstraZeneca, EU hold vaccine delivery talks
10:38aASTRAZENECA : uspicious package' evacuates COVID-19 vaccine plant in Wales
10:31aAZN EQUITY ALERT : Rosen Law Firm Announces Filing of Securities Class Action La..
More news
Financials (USD)
Sales 2020 26 379 M - -
Net income 2020 2 956 M - -
Net Debt 2020 13 464 M - -
P/E ratio 2020 43,7x
Yield 2020 2,58%
Capitalization 143 B 143 B -
EV / Sales 2020 5,95x
EV / Sales 2021 5,10x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 127,03 $
Last Close Price 109,27 $
Spread / Highest target 43,8%
Spread / Average Target 16,3%
Spread / Lowest Target -17,4%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON8.32%448 796
ROCHE HOLDING AG4.51%312 213
NOVARTIS AG0.81%214 457
PFIZER INC.1.36%207 384
MERCK & CO., INC.-1.89%203 035